| 54929-5 |
Tissue transglutaminase Ab |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Tissue transglutaminase Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
54929-5 |
|
IF |
|
|
Both |
|
|
|
0 |
tTG Ab Titr Ser IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Celiac disease; Dilution factor; Dilution Factor (Titer); FA; Fibrin stabilizing factor; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Point in time; Protein-glutamine gamma glutamyltransferase; Random; Serology; Serum; SmQn; SR; TG2; Time Resolved Fluorescence; Titer; Titered; Titre; TRF; tTG; Ttr |
2.75 |
2.27 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 5493-2 |
CD49c |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD49c cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5493-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD49c WBC-aCnc |
|
|
|
|
|
Alpha-3 integrin chain; Arbitrary concentration; CELL MARKERS; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; VLA-3 alpha chain; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 54930-3 |
Vicia faba Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Fava bean IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
54930-3 |
|
|
|
|
Both |
|
|
|
0 |
Fava bean IgE Qn |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Bell bean; Broad bean; Fava bean; Field bean; Horse bean; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Tic bean |
2.42 |
2.27 |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 54931-1 |
Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
54931-1 |
|
|
|
|
Both |
|
|
|
0 |
Isovaleryl+MeButyrylcarn/Creat Ur-sRto |
|
|
|
N |
|
C5; Chemistry; CR; Crea; Creat; Isovaleryl+MeButyrylcarn; Isovaleryl-2-Methylbutyrylcarnitine; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 54932-9 |
CEH abrine & ricinine panel |
MCnc |
Urine |
Pt |
- |
|
|
ACTIVE |
Centers for Environmental Health abrine and ricinine panel [Mass/volume] - Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
54932-9 |
|
|
|
|
Order |
|
|
|
0 |
CEH abrine+ricinine Pnl Ur-mCnc |
|
|
|
N |
|
Abrin; CEH abrine+ricinine Pnl; Centers for Environmental Health; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; Random; UA; UR; Urn |
2.42 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 54933-7 |
Abrine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Abrine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54933-7 |
|
|
|
|
Both |
|
|
|
0 |
Abrine Ur-mCnc |
|
|
|
N |
|
Abrin; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54934-5 |
Ricinine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Ricinine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54934-5 |
|
|
|
|
Both |
|
|
|
0 |
Ricinine Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54935-2 |
1,2-Dichloroethane |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
1,2-Dichloroethane [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54935-2 |
|
|
|
|
Both |
|
|
|
0 |
1,2DCA SerPl-mCnc |
|
|
|
N |
|
1,2DCA; 1,2-DCA; 1,2-Ethylene dichloride; DCA; DRUG/TOXICOLOGY; Drugs; EDC; Glycol dichloride; i; II; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54936-0 |
Carbon tetrachloride |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Carbon tetrachloride [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54936-0 |
|
|
|
|
Both |
|
|
|
0 |
Carbon Tet SerPl-mCnc |
|
|
|
N |
|
CCl4; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tetrachloromethane |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54937-8 |
Chloroform |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chloroform [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54937-8 |
|
|
|
|
Both |
|
|
|
0 |
Chloroform SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Formyl trichloride; Level; Mass concentration; Methane trichloride; Methenyl chloride; Methenyl trichloride; Methyl trichloride; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Trichloromethane |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54938-6 |
Ethyl benzene |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Ethyl benzene [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54938-6 |
|
|
|
|
Both |
|
|
|
0 |
Ethyl Benzene SerPl-mCnc |
|
|
|
N |
|
Cyclohexatriene; DRUG/TOXICOLOGY; Drugs; Ethylbenzene; Ethylbenzol; Level; Mass concentration; Phenylethane; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54939-4 |
Meta methylhippurate+Para methylhippurate |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Meta methylhippurate+Para methylhippurate [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54939-4 |
|
|
|
|
Both |
|
|
|
0 |
m+p-Methylhippurate SerPl-mCnc |
|
|
|
N |
|
3-methlhippurate; 4-methylhippurate; DRUG/TOXICOLOGY; Drugs; Level; m+p-Methylhippurate; Mass Concentration; Methylhippuric acid; m-methlhippurate; m-Methylhippurate; Para methylhippuric acid; Pl; Plasma; Plsm; p-methylhippurate; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Xylene metabolite |
2.73 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 5494-0 |
CD49d |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD49d cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5494-0 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD49d WBC-aCnc |
|
|
|
|
|
Alpha-4 integrin chain; Arbitrary concentration; CELL MARKERS; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; VLA-4 alpha chain; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 54940-2 |
Styrene |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Styrene [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54940-2 |
|
|
|
|
Both |
|
|
|
0 |
Styrene SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54941-0 |
Tungsten |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Tungsten [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54941-0 |
|
|
|
|
Both |
|
|
|
0 |
Tungsten Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; W |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54942-8 |
N-ethyldiethanolamine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
N-ethyldiethanolamine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54942-8 |
|
|
|
|
Both |
|
|
|
0 |
N-ethyldiethanolamine Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; EDEA; Ethyl diethanolamine; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54943-6 |
N-methyldiethanolamine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
N-methyldiethanolamine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54943-6 |
|
|
|
|
Both |
|
|
|
0 |
N-methyldiethanolamine Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; MDEA; Methyl diethanolamine; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54944-4 |
Monofluoroacetate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Monofluoroacetate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54944-4 |
|
|
|
|
Both |
|
|
|
0 |
Monofluoroacetate Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Monofluoroacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54945-1 |
Monochloroacetate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Monochloroacetate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
54945-1 |
|
|
|
|
Both |
|
|
|
0 |
Monochloroacetate Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Monochloroacetic acid; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.27 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 54946-9 |
Number of pressure injuries - unstageable due to coverage of wound bed by slough &or eschar |
Num |
^Patient |
RptPeriod |
Qn |
CMS Assessment |
|
ACTIVE |
Number of pressure injuries - unstageable due to coverage of wound bed by slough/eschar during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
SURVEY.CMS |
|
54946-9 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Cnt; Count; No; Num; Number; Pressure ulcer; Pressure Ulcers; QNT; Quan; Quant; Quantitative; Report period; Survey |
2.77 |
2.27 |
|
|
|
|
|
|
|
{#} |
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Previous Releases: Changed method from MDSv3 so term can be used across CMS assessments per decision by the Clinical LOINC committee and CMS HITWG; Removed "at assessment" from COMPONENT because it is implied by TIMING of "Pt";Updated COMPONENT from "and or" to "&or" to match convention; "Pressure ulcer" has been updated to "pressure injury" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC |
0 |
| 54947-7 |
Number of pressure injuries present upon admission &or reentry - unstageable due to coverage of wound bed by slough &or eschar |
Num |
^Patient |
RptPeriod |
Qn |
CMS Assessment |
|
ACTIVE |
Number of pressure injuries present upon admission/reentry - unstageable due to coverage of wound bed by slough/eschar during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
SURVEY.CMS |
|
54947-7 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Cnt; Count; No; Num; Number; Pressure ulcer; Pressure Ulcers; QNT; Quan; Quant; Quantitative; Report period; Survey |
2.77 |
2.27 |
|
|
|
|
|
|
|
{#} |
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Previous Releases: Changed method from MDSv3 so term can be used across CMS assessments per decision by the Clinical LOINC committee and CMS HITWG; "Pressure ulcer" has been updated to "pressure injury" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC |
0 |
| 54948-5 |
Date of onset of pressure ulcers onset in this facility - oldest or only unstageable due to coverage of wound bed by slough &or eschar |
TmStp |
^Patient |
Pt |
Qn |
MDSv3 |
|
DEPRECATED |
Deprecated Date of onset of pressure ulcers onset in this facility - oldest or only unstageable due to coverage of wound bed by slough &or eschar MDSv3 |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MDS |
|
54948-5 |
|
MDSv3 |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Date and time; Date of onset of pressure ulcers onset in this facility - oldest or only unstageable due to coverage of wound bed by slough/eschar; MDS version 3; Point in time; QNT; Quan; Quant; Quantitative; Random; Survey; SURVEY.MDS; Time stamp; Timestamp |
2.36 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 54949-3 |
Date of onset of pressure ulcers onset in this facility - newest unstageable due to coverage of wound bed by slough &or eschar |
TmStp |
^Patient |
Pt |
Qn |
MDSv3 |
|
DEPRECATED |
Deprecated Date of onset of pressure ulcers onset in this facility - newest unstageable due to coverage of wound bed by slough/eschar MDSv3 |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MDS |
|
54949-3 |
|
MDSv3 |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Date and time; Date of onset of pressure ulcers onset in this facility - newest unstageable due to coverage of wound bed by slough/eschar; MDS version 3; Point in time; QNT; Quan; Quant; Quantitative; Random; Survey; SURVEY.MDS; Time stamp; Timestamp |
2.36 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 5495-7 |
CD49E |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD49e cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5495-7 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD49E WBC-aCnc |
|
|
|
|
|
Alpha-5 integrin chain; Arbitrary concentration; CELL MARKERS; FNR alpha chain; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; VLA-5 alpha chain; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 54950-1 |
Number of pressure injuries - unstageable with suspected deep tissue injury in evolution |
Num |
^Patient |
RptPeriod |
Qn |
CMS Assessment |
|
ACTIVE |
Number of pressure injuries - unstageable with suspected deep tissue injury in evolution during assessment period [CMS Assessment] |
|
MAJ |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
SURVEY.CMS |
|
54950-1 |
|
CMS Assessment |
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Cnt; Count; No; Num; Number; Pressure ulcer; Pressure Ulcers; QNT; Quan; Quant; Quantitative; Report period; Survey; Ulcer |
2.77 |
2.27 |
|
|
|
|
|
|
|
{#} |
|
|
Release 2.77: TIME_ASPCT: Decision by CMS to update the Timing to RptPeriod from Pt for all CMS Assessments; Previous Releases: Changed method from MDSv3 so term can be used across CMS assessments per decision by the Clinical LOINC committee and CMS HITWG; Removed "at assessment" from COMPONENT because it is implied by TIMING of "Pt"; "Pressure ulcer" has been updated to "pressure injury" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC |
0 |
